At Biomet, engineering excellence is our heritage and our passion. For over 25 years, through various divisions worldwide, we have applied the most advanced engineering and manufacturing technology to the development of highly durable systems for a wide variety of surgical applications.

StaGraft™ DBM
Biomet...
Shaping the Future of DBM

To learn more about this product, contact your local Biomet Sales Representative today.

References

1. Biomet Internal Test Report (TR-0894)


All trademarks herein are the property of Biomet, Inc. or its subsidiaries unless otherwise indicated.

This material is intended for the Biomet Sales force and physicians only and is NOT intended for patient distribution. It is not to be redistributed, duplicated or disclosed without the express written consent of Biomet.

For product information, including indications, contraindications, warnings, precautions and potential adverse effects, see the package insert and the patient risk information at www.biomet.com.

Animal studies are not necessarily indicative of human clinical outcomes.

Bench testing is not necessarily indicative of clinical performance.
StaGraft™
Demineralized Bone Matrix
StaGraft™ DBM is a osteoinductive demineralized bone matrix in a natural lecithin carrier, and is available as a 40% DBM putty, or 35% DBM Plus pre-mixed with resorbable coralline hydroxyapatite granules.

The natural quality of the carrier and its outstanding containment and handling characteristics enable the surgeon to mold it to surgical sites, even in the presence of excessive fluids and under lavage.

StaGraft™ DBM Family

Each lot is verified for osteoinductivity via the validated “C2C12” assay.

- DBM is resistant to wash-out during implantation – formulated with a natural lipid carrier that is resistant to breakdown by bodily fluids or temperature

- Excellent handling and performance characteristics – tolerates lavage/irrigation

- DBM-to-carrier ratio engineered for optimized osteoinductivity

- Every lot is bioassayed to demonstrate osteoinductive capabilities

- Off-the-shelf, moldable tissue graft; no mixing required – use with your preferred technique

- StaGraft™ Plus with Pro Osteon® 500R Resorbable Granules has excellent handling properties

- Easy to use – pre-loaded in a syringe; stored at room temperature

- Donor testing – all tissue undergoes extensive viral, microbiological and serological testing; HIV/PCR testing is done on every donor

- Comes in an array of convenient delivery sizes for a range of uses
StaGraft™ DBM + Lecithin (100x)

Osteoinductivity Percent DBM

4 Weeks Post-Op
- Intramuscular and subcutaneous implantation sites
- Abundant bone growth is shown in the DBM + Lecithin implant
- Total bone and tissue volume increased in the DBM + Lecithin implant

Urist found that endogenous lipids are closely associated with BMP and facilitate heterotopic bone formation.

27 Fisher rats, sub-Q and IM 28 day implantation. H&E staining

Non-Toxicity of Lecithin

<table>
<thead>
<tr>
<th>Dosage (per 100g rat)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>.8g</td>
<td>100% Alive and Asymptomatic</td>
</tr>
<tr>
<td>1.6g</td>
<td>100% Alive and Asymptomatic</td>
</tr>
<tr>
<td>2.0g</td>
<td>100% Alive and Asymptomatic</td>
</tr>
</tbody>
</table>

In an animal model, rats were implanted with lecithin grafts to determine the overall level of toxicity.

All the rats exposed to the lecithin grafts lived and remained asymptomatic.

Alkaline phosphatase activity (ALP) is a measurement of osteoinductivity.

In an animal model, rats were implanted with lecithin grafts to determine the overall level of toxicity.

All the rats exposed to the lecithin grafts lived and remained asymptomatic.

Urist found that endogenous lipids are closely associated with BMP and facilitate heterotopic bone formation.

27 Fisher rats, sub-Q and IM 28 day implantation. H&E staining